blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2616078

EP2616078 - FULVESTRANT COMPOSITIONS AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.10.2020
Database last updated on 06.11.2024
FormerThe patent has been granted
Status updated on  22.11.2019
FormerGrant of patent is intended
Status updated on  16.07.2019
FormerExamination is in progress
Status updated on  05.10.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Shimoda Biotech (Pty) Ltd
Bosky Dell Farm
6600 Plettenberg Bay / ZA
[2019/52]
Former [2013/30]For all designated states
Shimoda Biotech (Pty) Ltd
Bosky Dell Farm
6600 Plettenberg Bay / ZA
Inventor(s)01 / SWART, Henk
Bosky Dell Farm
6600 Plettenberg Bay / ZA
 [2013/30]
Representative(s)Appleyard Lees IP LLP
15 Clare Road
Halifax HX1 2HY / GB
[2019/52]
Former [2013/30]Waddington, Richard, et al
Appleyard Lees
15 Clare Road
Halifax HX1 2HY / GB
Application number, filing date11824680.016.09.2011
[2019/52]
WO2011IB54058
Priority number, dateUS20100383660P16.09.2010         Original published format: US 383660 P
[2013/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012035516
Date:22.03.2012
Language:EN
[2012/12]
Type: A1 Application with search report 
No.:EP2616078
Date:24.07.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 22.03.2012 takes the place of the publication of the European patent application.
[2013/30]
Type: B1 Patent specification 
No.:EP2616078
Date:25.12.2019
Language:EN
[2019/52]
Search report(s)International search report - published on:AT22.03.2012
(Supplementary) European search report - dispatched on:EP15.04.2016
ClassificationIPC:A61K47/69, C08B37/16, A61K47/40, A61K31/565, // A61P35/00, B82Y5/00
[2019/30]
CPC:
A61K31/565 (EP,US); A61K31/566 (EP,US); A61K47/40 (EP,US);
A61K47/549 (US); A61K47/6951 (EP,US); A61K9/0065 (EP,US);
A61K9/0095 (EP,US); A61K9/08 (US); A61K9/2018 (EP,US);
A61K9/2054 (EP,US); A61P35/00 (EP); A61P35/04 (EP);
A61P37/00 (EP); A61P5/32 (EP); C08B37/0015 (EP,US);
A61K9/0043 (EP,US); B82Y5/00 (EP,US) (-)
Former IPC [2016/20]A61K47/48, C08B37/16, A61K31/565, A61K47/40, // A61P35/00, B82Y5/00
Former IPC [2013/30]A61K31/565, A61K47/40
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/30]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:FULVESTRANT-ZUSAMMENSETZUNGEN UND VERWENDUNGSVERFAHREN DAFÜR[2013/30]
English:FULVESTRANT COMPOSITIONS AND METHODS OF USE[2013/30]
French:COMPOSITIONS À BASE DE FULVESTRANT, ET PROCÉDÉS D'UTILISATION[2013/30]
Entry into regional phase15.04.2013National basic fee paid 
15.04.2013Search fee paid 
15.04.2013Designation fee(s) paid 
15.04.2013Examination fee paid 
Examination procedure15.04.2013Examination requested  [2013/30]
11.11.2016Amendment by applicant (claims and/or description)
05.10.2018Despatch of a communication from the examining division (Time limit: M04)
15.02.2019Reply to a communication from the examining division
17.07.2019Communication of intention to grant the patent
14.11.2019Fee for grant paid
14.11.2019Fee for publishing/printing paid
14.11.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.10.2018
Opposition(s)28.09.2020No opposition filed within time limit [2020/49]
Fees paidRenewal fee
26.09.2013Renewal fee patent year 03
25.09.2014Renewal fee patent year 04
28.09.2015Renewal fee patent year 05
13.09.2016Renewal fee patent year 06
12.09.2017Renewal fee patent year 07
11.09.2018Renewal fee patent year 08
13.09.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.09.2011
AL25.12.2019
AT25.12.2019
CY25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
MK25.12.2019
MT25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
TR25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
[2022/32]
Former [2022/27]HU16.09.2011
AL25.12.2019
AT25.12.2019
CY25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
MT25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
TR25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
Former [2022/26]AL25.12.2019
AT25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
TR25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
Former [2021/23]AL25.12.2019
AT25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
Former [2021/11]AL25.12.2019
AT25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
Former [2020/51]AL25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
Former [2020/47]AL25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
Former [2020/40]AL25.12.2019
CZ25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
Former [2020/37]AL25.12.2019
CZ25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/35]AL25.12.2019
CZ25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/32]AL25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/25]FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/23]FI25.12.2019
LT25.12.2019
LV25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/22]FI25.12.2019
LT25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
Former [2020/21]NO25.03.2020
Documents cited:Search[Y]US4596795  (PITHA JOSEF [US]) [Y] 1-35 * example - ** claim - *;
 [Y]WO9602277  (SCHERING AG [DE], et al) [Y] 1-35 * page 2 * * example - *;
 [Y]EP1568381  (KYOWA HAKKO KOGYO KK [JP]) [Y] 1-35 * example - *;
 [Y]  - ROBERTSON J F R, "Fulvestrant (Faslodex(R)) - How to make a good drug better", THE ONCOLOGIST, (200707), vol. 12, no. 7, doi:10.1634/THEONCOLOGIST.12-7-774, ISSN 1083-7159, pages 774 - 784, XP002612296 [Y] 1-35 * abstract * * page 775, column r, paragraph l - page 782 *

DOI:   http://dx.doi.org/10.1634/theoncologist.12-7-774
 [Y]  - THOMPSON M J ET AL, "Sugar conjugates of fulvestrant (ICI 182,780): efficient general procedures for glycosylation of the fulvestrant core", TETRAHEDRON LETTERS, (20040202), vol. 45, no. 6, doi:10.1016/J.TETLET.2003.11.140, ISSN 0040-4039, pages 1207 - 1210, XP004484815 [Y] 1-35 * abstract * * page 1208 - page 1209 *

DOI:   http://dx.doi.org/10.1016/j.tetlet.2003.11.140
 [Y]  - JOURNÉ FABRICE ET AL, "Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.", EXPERT OPINION ON DRUG SAFETY, (200805), vol. 7, no. 3, doi:10.1517/14740338.7.3.241, ISSN 1744-764X, pages 241 - 258, XP002756222 [Y] 1-35 * abstract * * figure - * * page 246 - page 247 * * page 251 - page 252 *

DOI:   http://dx.doi.org/10.1517/14740338.7.3.241
 [Y]  - KABOS PETER ET AL, "Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.", EXPERT OPINION ON PHARMACOTHERAPY, (201004), vol. 11, no. 5, doi:10.1517/14656561003641982, ISSN 1744-7666, pages 807 - 816, XP002756223 [Y] 1-35 * abstract * * page 808 - page 809, column l * * figure - *

DOI:   http://dx.doi.org/10.1517/14656561003641982
 [Y]  - LOFTSSON T ET AL, "Evaluation of cyclodextrin solubilization of drugs", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (20050930), vol. 302, no. 1-2, ISSN 0378-5173, pages 18 - 28, XP027624216 [Y] 1-35 * abstract * * page 18, paragraph Introduction - page 19, column l * * table - *
International search[A]US2004024044  (DI SALLE ENRICO [IT], et al);
 [A]US2005043285  (EVANS JOHN R [GB], et al);
 [A]WO2007044662  (SICOR INC [US], et al);
 [X]US2009099265  (VAN AS ANDRE [US])
Examination   - RAJEWSKI R A ET AL, "PHARMACEUTICAL APPLICATIONS OF CYCLODEXTRINS. 2. IN VIVO DRUG DELIVERY", JOURNAL OF PHARMACEUTICAL SCIENCES, (19961101), vol. 85, no. 11, doi:10.1021/JS960075U, ISSN 0022-3549, pages 1142 - 1169, XP000629515

DOI:   http://dx.doi.org/10.1021/js960075u
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.